Supernus Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary

Supernus Pharmaceuticals

04/08/2026 22:01

Supernus Pharmaceuticals Inc SUPN.OQ reported quarterly adjusted earnings of 53 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of 90 cents.  The mean expectation of six analysts for the quarter was for earnings of 42 cents per share. Wall Street expected results to range from 15 cents to 64 cents per share.
Revenue rose 32.4% to $219.06 million from a year ago; analysts expected $204.96 million. 
Supernus Pharmaceuticals Inc's reported EPS for the quarter was a loss of $1.01​.
The company reported a quarterly loss of $58.37 million.
Supernus Pharmaceuticals Inc shares had fallen by 1.1% this quarter and lost 7.4% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 4% in the last three months.​ 
In the last 30 days, two analysts negatively revised earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy" 
Wall Street's median 12-month price target for Supernus Pharmaceuticals Inc is $65.00, about 29.2% above its last closing price of $46.00
This summary was machine generated from LSEG data August 4 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
0.42
0.53
Beat
Mar. 31 2026 
0.30
0.60
Beat
Dec. 31 2025 
0.34
0.84
Beat
Sep. 30 2025 
0.59
1.01
Beat